Αποτελέσματα Αναζήτησης
In this review, we discuss relevant mechanisms of potential cardiovascular risks related to marijuana, discuss pharmacological interactions with common cardiovascular therapies, and synthesize a practical approach to approaching marijuana use in cardiovascular clinical care settings.
17 Νοε 2023 · The clinical manifestations and management of toxicity from cannabis (marijuana), cannabis withdrawal, epidemiology of cannabis use, and cannabis use disorder are discussed separately.
The 2022 MASCC guideline on cannabinoids for GI symptoms in adults with cancer suggests against use of cannabinoids in the following circumstances: treatment of nausea and vomiting unrelated to chemotherapy; first-line treatment in the prevention of CINV; and prevention of radiotherapy-induced nausea and vomiting. 40 The MASCC guideline ...
2 Νοε 2018 · Vaporized cannabis resulted in qualitatively stronger drug effects for most pharmacodynamic outcomes and higher peak concentrations of THC in blood, compared with equal doses of smoked cannabis (25-mg dose: smoked, 10.2 ng/mL; vaporized, 14.4 ng/mL).
12 Ιαν 2017 · Chapter Highlights. In adults with chemotherapy-induced nausea and vomiting, oral cannabinoids are effective antiemetics. In adults with chronic pain, patients who were treated with cannabis or cannabinoids are more likely to experience a clinically significant reduction in pain symptoms.
We developed 10 major recommendations for lower-risk use: (1) the most effective way to avoid cannabis use–related health risks is abstinence, (2) avoid early age initiation of cannabis use (i.e., definitively before the age of 16 years), (3) choose low-potency tetrahydrocannabinol (THC) or balanced THC-to-cannabidiol (CBD)–ratio cannabis ...
8 Δεκ 2021 · Increased potency of cannabis products, combined with advanced delivery systems such as vaping devices (for use with cannabis flower—dried buds of the cannabis plant—or concentrates, such as “wax” and “shatter”) have contributed to increasing risk for adverse outcomes .
